Table 3 Associations between BMI and time to death.

From: An optimal BMI range associated with a lower risk of mortality among HIV-infected adults initiating antiretroviral therapy in Guangxi, China

 

BMI < 18.5

18.5 ≤ BMI < 24

24 ≤ BMI < 28

BMI ≥ 28

Number of events

1439

3047

548

67

Time on antiretroviral treatment (person-years)

3493.1

7595.2

1243.6

127.9

AHRa (95% CI), p value

—

0.5 (0.4–0.7), <0.001

0.3 (0.1–0.6), 0.002

1.3 (0.4–4.2), 0.705

Number of patients who have virus load records

354

693

117

12

Time on antiretroviral treatment (person-years)

1450.3

2821.6

456.8

45.9

AHRb (95% CI), p value

—

0.5 (0.3–0.9), 0.031

—

3.2 (0.6–17.3), 0.187

  1. AHRa: adjusted by age, gender, marital status, baseline BMI, baseline CD4 T cell count, and clinical disease (including TB infection, Skin lesion, thrush, oral hairy leukoplakia, persistent diarrhoea, continuous or intermittent fever, recurrent severe bacterial infections, disseminated non-tuberculosis bacillus infection, oesophageal candidiasis, extrapulmonary cryptococcal infection, Yersinia pneumocystis pneumonia, disseminated fungal disease, cytomegalovirus infection, extrapulmonary tuberculosis, repeated severe bacterial pneumonia, chronic herpes simplex virus infection, herpes zoster, Toxoplasma encephalopathy, brain lymphoma, and WHO clinical stage).
  2. AHRb: adjusted by the viral load on the basis of the AHRa.
Back to article page